serine has been researched along with Cognition Disorders in 46 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These findings represent the first randomized double-blind placebo-controlled study with 60mg/kg d-serine in schizophrenia, and are consistent with meta-analyses showing significant effects of d-serine in schizophrenia." | 9.27 | Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. ( Epstein, ML; Javitt, DC; Kantrowitz, JT; Lee, M; Lehrfeld, N; Nolan, KA; Petkova, E; Shope, C; Silipo, G, 2018) |
| "D-serine is an allosteric modulator of the brain N-methyl-d-aspartate (NMDA) receptor and a potential novel treatment of schizophrenia." | 9.14 | High dose D-serine in the treatment of schizophrenia. ( Balla, A; Cornblatt, B; D'Souza, C; Javitt, DC; Kantrowitz, JT; Malhotra, AK; Saksa, J; Silipo, G; Suckow, RF; Woods, SW, 2010) |
| "Schizophrenia is a severe psychiatric illness that is characterized by reduced cortical connectivity, for which the underlying biological and genetic causes are not well understood." | 6.52 | The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. ( Balu, DT; Coyle, JT, 2015) |
| "Schizophrenia is characterized by reduced hippocampal volume, decreased dendritic spine density, altered neuroplasticity signaling pathways, and cognitive deficits associated with impaired hippocampal function." | 5.39 | Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. ( Balu, DT; Basu, AC; Benneyworth, MA; Bolshakov, VY; Coyle, JT; Li, Y; Puhl, MD; Takagi, S, 2013) |
| "These findings represent the first randomized double-blind placebo-controlled study with 60mg/kg d-serine in schizophrenia, and are consistent with meta-analyses showing significant effects of d-serine in schizophrenia." | 5.27 | Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. ( Epstein, ML; Javitt, DC; Kantrowitz, JT; Lee, M; Lehrfeld, N; Nolan, KA; Petkova, E; Shope, C; Silipo, G, 2018) |
| "D-serine is an allosteric modulator of the brain N-methyl-d-aspartate (NMDA) receptor and a potential novel treatment of schizophrenia." | 5.14 | High dose D-serine in the treatment of schizophrenia. ( Balla, A; Cornblatt, B; D'Souza, C; Javitt, DC; Kantrowitz, JT; Malhotra, AK; Saksa, J; Silipo, G; Suckow, RF; Woods, SW, 2010) |
| "We report on two new cases of serine deficiency due respectively to 3-phosphoglycerate dehydrogenase (PHGDH) deficiency (Patient 1) and phosphoserine aminotransferase (PSAT1) deficiency (Patient 2), presenting with congenital microcephaly (<3rd centile at birth) and encephalopathy with spasticity." | 3.83 | Two new cases of serine deficiency disorders treated with l-serine. ( Bahi-Buisson, N; Boddaert, N; Brassier, A; de Lonlay, P; Desguerre, I; Habarou, F; Hubert, L; Kaminska, A; Ottolenghi, C; Valayannopoulos, V; Van Schaftingen, E; Wiame, E, 2016) |
| "Schizophrenia is a severe psychiatric illness that is characterized by reduced cortical connectivity, for which the underlying biological and genetic causes are not well understood." | 2.52 | The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. ( Balu, DT; Coyle, JT, 2015) |
| "Current treatments for schizophrenia, although effective for positive symptoms, have not proven as effective for negative symptoms and cognitive dysfunction." | 2.50 | Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. ( Citrome, L, 2014) |
| "Patients with Parkinson's disease have reduced gray matter volume and fractional anisotropy in both cortical and sub-cortical structures, yet changes in the pre-motor phase of the disease are unknown." | 1.40 | A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers. ( Artzi, M; Ben Bashat, D; Bloem, BR; Bressman, S; Giladi, N; Gurevich, T; Helmich, RC; Hendler, T; Jacob, Y; Marder, K; Mirelman, A; Orr-Urtreger, A; Thaler, A; van Nuenen, BF, 2014) |
| "Schizophrenia is characterized by reduced hippocampal volume, decreased dendritic spine density, altered neuroplasticity signaling pathways, and cognitive deficits associated with impaired hippocampal function." | 1.39 | Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. ( Balu, DT; Basu, AC; Benneyworth, MA; Bolshakov, VY; Coyle, JT; Li, Y; Puhl, MD; Takagi, S, 2013) |
| "Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a nonlesional condition associated with mutation of the gene coding for the alpha4 nicotinic acetylcholine receptor (nAChR)." | 1.36 | Neuropsychological function in patients with a single gene mutation associated with autosomal dominant nocturnal frontal lobe epilepsy. ( Benjamin, C; Berkovic, SF; Fedi, M; Reutens, DC; Saling, MM; Scheffer, IE; Wood, AG, 2010) |
| " The right medial superior frontal gyrus volume was significantly correlated with daily dosage of antipsychotic medication in Ser homozygote schizophrenia patients." | 1.35 | The Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain morphology in schizophrenia. ( Hagino, H; Kawasaki, Y; Kobayashi, S; Kurachi, M; Maeno, N; Niu, L; Ozaki, N; Sasaoka, T; Seto, H; Suzuki, M; Takahashi, T; Tsuneki, H; Tsunoda, M; Zhou, SY, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.35) | 18.7374 |
| 1990's | 2 (4.35) | 18.2507 |
| 2000's | 9 (19.57) | 29.6817 |
| 2010's | 32 (69.57) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Fone, KCF | 1 |
| Watson, DJG | 1 |
| Billiras, RI | 1 |
| Sicard, DI | 1 |
| Dekeyne, A | 1 |
| Rivet, JM | 1 |
| Gobert, A | 1 |
| Millan, MJ | 1 |
| Kantrowitz, JT | 2 |
| Epstein, ML | 1 |
| Lee, M | 1 |
| Lehrfeld, N | 1 |
| Nolan, KA | 1 |
| Shope, C | 1 |
| Petkova, E | 1 |
| Silipo, G | 2 |
| Javitt, DC | 3 |
| Sardinha, VM | 1 |
| Guerra-Gomes, S | 1 |
| Caetano, I | 1 |
| Tavares, G | 1 |
| Martins, M | 1 |
| Reis, JS | 1 |
| Correia, JS | 1 |
| Teixeira-Castro, A | 1 |
| Pinto, L | 1 |
| Sousa, N | 1 |
| Oliveira, JF | 1 |
| Liraz-Zaltsman, S | 1 |
| Slusher, B | 1 |
| Atrakchi-Baranes, D | 1 |
| Rosenblatt, K | 1 |
| Friedman Levi, Y | 1 |
| Kesner, E | 1 |
| Silva, AJ | 1 |
| Biegon, A | 1 |
| Shohami, E | 1 |
| Ji, M | 1 |
| Xie, XX | 1 |
| Liu, DQ | 1 |
| Yu, XL | 1 |
| Zhang, Y | 1 |
| Zhang, LX | 1 |
| Wang, SW | 1 |
| Huang, YR | 1 |
| Liu, RT | 1 |
| Balu, DT | 2 |
| Li, Y | 1 |
| Puhl, MD | 1 |
| Benneyworth, MA | 1 |
| Basu, AC | 1 |
| Takagi, S | 1 |
| Bolshakov, VY | 1 |
| Coyle, JT | 2 |
| Hausner, L | 1 |
| Tschäpe, JA | 1 |
| Schmitt, HP | 1 |
| Hentschel, F | 1 |
| Hartmann, T | 1 |
| Frölich, L | 1 |
| Klatte, K | 1 |
| Kirschstein, T | 1 |
| Otte, D | 1 |
| Pothmann, L | 1 |
| Müller, L | 1 |
| Tokay, T | 1 |
| Kober, M | 1 |
| Uebachs, M | 1 |
| Zimmer, A | 1 |
| Beck, H | 1 |
| Onishi, T | 1 |
| Matsumoto, Y | 1 |
| Hattori, M | 1 |
| Obayashi, Y | 1 |
| Nakamura, K | 1 |
| Yano, T | 1 |
| Horiguchi, T | 1 |
| Iwashita, H | 1 |
| Panizzutti, R | 3 |
| Scoriels, L | 2 |
| Avellar, M | 2 |
| Thaler, A | 1 |
| Artzi, M | 1 |
| Mirelman, A | 1 |
| Jacob, Y | 1 |
| Helmich, RC | 1 |
| van Nuenen, BF | 1 |
| Gurevich, T | 1 |
| Orr-Urtreger, A | 1 |
| Marder, K | 1 |
| Bressman, S | 2 |
| Bloem, BR | 1 |
| Hendler, T | 1 |
| Giladi, N | 1 |
| Ben Bashat, D | 1 |
| Citrome, L | 1 |
| Li, C | 1 |
| Liu, S | 1 |
| Xing, Y | 1 |
| Tao, F | 1 |
| Guercio, GD | 1 |
| Bevictori, L | 1 |
| Vargas-Lopes, C | 2 |
| Madeira, C | 2 |
| Oliveira, A | 1 |
| Carvalho, VF | 1 |
| d'Avila, JC | 1 |
| Matsuura, A | 1 |
| Fujita, Y | 2 |
| Iyo, M | 2 |
| Hashimoto, K | 3 |
| Brassier, A | 1 |
| Valayannopoulos, V | 1 |
| Bahi-Buisson, N | 1 |
| Wiame, E | 1 |
| Hubert, L | 1 |
| Boddaert, N | 1 |
| Kaminska, A | 1 |
| Habarou, F | 1 |
| Desguerre, I | 1 |
| Van Schaftingen, E | 1 |
| Ottolenghi, C | 1 |
| de Lonlay, P | 1 |
| Marques, P | 1 |
| Dantas, C | 1 |
| Manhães, AC | 1 |
| Leite, H | 1 |
| Zou, C | 1 |
| Crux, S | 1 |
| Marinesco, S | 1 |
| Montagna, E | 1 |
| Sgobio, C | 1 |
| Shi, Y | 1 |
| Shi, S | 1 |
| Zhu, K | 1 |
| Dorostkar, MM | 1 |
| Müller, UC | 1 |
| Herms, J | 1 |
| Alkam, T | 1 |
| Nitta, A | 1 |
| Mizoguchi, H | 1 |
| Itoh, A | 1 |
| Murai, R | 1 |
| Nagai, T | 2 |
| Yamada, K | 2 |
| Nabeshima, T | 2 |
| Takahashi, T | 1 |
| Suzuki, M | 1 |
| Tsunoda, M | 1 |
| Maeno, N | 1 |
| Kawasaki, Y | 1 |
| Zhou, SY | 1 |
| Hagino, H | 1 |
| Niu, L | 1 |
| Tsuneki, H | 1 |
| Kobayashi, S | 1 |
| Sasaoka, T | 1 |
| Seto, H | 1 |
| Kurachi, M | 1 |
| Ozaki, N | 1 |
| Adcock, RA | 1 |
| Dale, C | 1 |
| Fisher, M | 1 |
| Aldebot, S | 1 |
| Genevsky, A | 1 |
| Simpson, GV | 1 |
| Nagarajan, S | 1 |
| Vinogradov, S | 1 |
| Bryan, KJ | 1 |
| Mudd, JC | 1 |
| Richardson, SL | 1 |
| Chang, J | 1 |
| Lee, HG | 1 |
| Zhu, X | 1 |
| Smith, MA | 1 |
| Casadesus, G | 1 |
| Sharma, A | 1 |
| Hoeffer, CA | 1 |
| Takayasu, Y | 1 |
| Miyawaki, T | 1 |
| McBride, SM | 1 |
| Klann, E | 1 |
| Zukin, RS | 1 |
| Piscopo, P | 1 |
| Talarico, G | 1 |
| Crestini, A | 1 |
| Gasparini, M | 1 |
| Malvezzi-Campeggi, L | 1 |
| Piacentini, E | 1 |
| Lenzi, GL | 1 |
| Bruno, G | 1 |
| Confaloni, A | 1 |
| Wood, AG | 1 |
| Saling, MM | 1 |
| Fedi, M | 1 |
| Berkovic, SF | 1 |
| Scheffer, IE | 1 |
| Benjamin, C | 1 |
| Reutens, DC | 1 |
| Gomez, A | 1 |
| Ferrer, I | 1 |
| Malhotra, AK | 1 |
| Cornblatt, B | 1 |
| Balla, A | 1 |
| Suckow, RF | 1 |
| D'Souza, C | 1 |
| Saksa, J | 1 |
| Woods, SW | 1 |
| Forlenza, OV | 1 |
| Torres, CA | 1 |
| Talib, LL | 1 |
| de Paula, VJ | 1 |
| Joaquim, HP | 1 |
| Diniz, BS | 1 |
| Gattaz, WF | 1 |
| Caudal, D | 1 |
| Godsil, BP | 1 |
| Mailliet, F | 1 |
| Bergerot, D | 1 |
| Jay, TM | 1 |
| Cuadrado-Tejedor, M | 1 |
| Ricobaraza, A | 1 |
| Del Río, J | 1 |
| Frechilla, D | 1 |
| Franco, R | 1 |
| Pérez-Mediavilla, A | 1 |
| Garcia-Osta, A | 1 |
| Shanker, V | 1 |
| Groves, M | 1 |
| Heiman, G | 1 |
| Palmese, C | 1 |
| Saunders-Pullman, R | 1 |
| Ozelius, L | 1 |
| Raymond, D | 1 |
| Troquier, L | 1 |
| Caillierez, R | 1 |
| Burnouf, S | 1 |
| Fernandez-Gomez, FJ | 1 |
| Grosjean, ME | 1 |
| Zommer, N | 1 |
| Sergeant, N | 1 |
| Schraen-Maschke, S | 1 |
| Blum, D | 1 |
| Buee, L | 1 |
| Stetler, RA | 1 |
| Gao, Y | 1 |
| Zhang, L | 1 |
| Weng, Z | 1 |
| Zhang, F | 1 |
| Hu, X | 1 |
| Wang, S | 1 |
| Vosler, P | 1 |
| Cao, G | 1 |
| Sun, D | 1 |
| Graham, SH | 1 |
| Chen, J | 1 |
| Yu, J | 1 |
| Kitahara, Y | 1 |
| Ohnuma, T | 1 |
| Sakai, Y | 1 |
| Maeshima, H | 1 |
| Higa, M | 1 |
| Hanzawa, R | 1 |
| Kitazawa, M | 1 |
| Hotta, Y | 1 |
| Katsuta, N | 1 |
| Takebayashi, Y | 1 |
| Shibata, N | 1 |
| Arai, H | 1 |
| Yang, SN | 1 |
| Huang, LT | 1 |
| Wang, CL | 1 |
| Chen, WF | 1 |
| Yang, CH | 1 |
| Lin, SZ | 1 |
| Lai, MC | 1 |
| Chen, SJ | 1 |
| Tao, PL | 1 |
| Maccioni, RB | 1 |
| Lavados, M | 1 |
| Guillón, M | 1 |
| Mujica, C | 1 |
| Bosch, R | 1 |
| Farías, G | 1 |
| Fuentes, P | 1 |
| Shang, HF | 1 |
| Jiang, XF | 1 |
| Burgunder, JM | 1 |
| Chen, Q | 1 |
| Zhou, D | 1 |
| Tumini, E | 1 |
| Porcellini, E | 1 |
| Chiappelli, M | 1 |
| Conti, CM | 1 |
| Beraudi, A | 1 |
| Poli, A | 1 |
| Caciagli, F | 1 |
| Doyle, R | 1 |
| Conti, P | 1 |
| Licastro, F | 1 |
| Ishima, T | 1 |
| Chaki, S | 2 |
| Karasawa, J | 1 |
| Ramakers, GM | 1 |
| Urban, IJ | 1 |
| De Graan, PN | 1 |
| Di Luca, M | 1 |
| Cattabeni, F | 1 |
| Gispen, WH | 1 |
| Yanai, Y | 1 |
| Shibasaki, T | 1 |
| Kohno, N | 1 |
| Mitsui, T | 1 |
| Nakajima, H | 1 |
| Usui, S | 1 |
| Komiya, T | 1 |
| Imai, H | 1 |
| Narabayashi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of an NMDA-based Intervention on Biomarker Measures of Cognitive Dysfunction in Schizophrenia[NCT00817336] | Phase 2 | 16 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| PK/PD Study of Escalating Dose D-serine as Adjunctive Treatment in Schizophrenia[NCT00322023] | Phase 2 | 55 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder[NCT01116830] | Phase 1 | 29 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia[NCT01891721] | 105 participants (Actual) | Interventional | 2013-11-21 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MATRICS assessing 7 domains (Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition. Raw scores are converted into a composite T-score (normative mean = 50; standard deviation = 10), where higher values indicated less impairment. (NCT00817336)
Timeframe: 6 weeks
| Intervention | T score (Mean) |
|---|---|
| D-serine | 26.2 |
| Placebo | 25.7 |
Final MMN amplitude (NCT00817336)
Timeframe: 6 weeks
| Intervention | micro volts (Mean) |
|---|---|
| D-serine | -1.21 |
| Placebo | -.21 |
Positive and Negative Symptom Scale (PANSS) range 30-210 (NCT00817336)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine | 77.9 |
| Placebo | 80 |
(NCT00817336)
Timeframe: 6 weeks
| Intervention | micro volts (Mean) |
|---|---|
| D-serine | -.21 |
| Placebo | -.54 |
Change over 4 weeks. The MATRICS is a scale measuring cognition, and reported as T-score, with 50 as the population average and every 10 points representing a change of 1 standard deviation from the population average. Higher scores represent an improvement (NCT00322023)
Timeframe: Measured at Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine 30 mg/kg | 0.8 |
| D-serine 60 mg/kg | 3.9 |
| D Serine 120 mg/kg | 2.8 |
Absolute Change in PANSS over four weeks (change between baseline and final measurements). The PANSS is a 30-item rating scale widely used in assessment of medication effects in schizophrenia. The PANSS ranges from 30-210, with lower scores showing less symptoms. Larger change is better. (NCT00322023)
Timeframe: Measured at Week 4
| Intervention | units on a scale (Mean) |
|---|---|
| D-serine 30 mg/kg | 5.1 |
| D-serine 60 mg/kg | 4.4 |
| D Serine 120 mg/kg | 6.3 |
number of renal adverse events (serum and urinalysis) (NCT00322023)
Timeframe: Measured at Week 4
| Intervention | adverse events (Number) |
|---|---|
| D-serine 30 mg/kg | 0 |
| D-serine 60 mg/kg | 0 |
| D Serine 120 mg/kg | 1 |
The University of California San Diego (UCSD) Performance-based Skills Assessment (UPSA) was used to assess functional capacity. The UPSA total score served as a secondary functional outcome measure. Minimum and maximum values are 40 and 100. Higher scores mean a better outcome. (NCT01891721)
Timeframe: Within one week of training completion
| Intervention | score on a scale (Mean) |
|---|---|
| Specific Auditory Training - Brain Fitness Program (BFP) | 76.50 |
| Broad Cognitive Training - Cognitive Package (Cogpack) | 75.96 |
| Control Treatment - Commercial Computer Games (Sporcle) | 76.77 |
The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) was used to assess basic cognition. It includes tests representing 6 separable cognitive domains. The MCCB composite score (average of 6 domain t-scores) served as the primary cognitive outcome measure. Minimum and maximum values are 20 and 68. Higher scores mean a better outcome. (NCT01891721)
Timeframe: Within one week of training completion
| Intervention | score on a scale (Mean) |
|---|---|
| Specific Auditory Training - Brain Fitness Program (BFP) | 42.02 |
| Broad Cognitive Training - Cognitive Package (Cogpack) | 41.92 |
| Control Treatment - Commercial Computer Games (Sporcle) | 41.94 |
A Mismatch Negativity (MMN) Paradigm was used to assess basic auditory processing. MMN amplitude was measured as the mean voltage in the 145-200 ms latency range at pooled frontocentral electodes. Minimum and maximum values are -8 and +2 microvolts. More negative scores mean a better outcome. (NCT01891721)
Timeframe: After 6 weeks of training and within one week of training completion
| Intervention | units on a scale (Mean) | |
|---|---|---|
| MMN at 12 weeks | MMN at 6 weeks | |
| Broad Cognitive Training - Cognitive Package (Cogpack) | -2.17 | -2.16 |
| Control Treatment - Commercial Computer Games (Sporcle) | -2.09 | -2.21 |
| Specific Auditory Training - Brain Fitness Program (BFP) | -2.04 | -1.78 |
5 reviews available for serine and Cognition Disorders
| Article | Year |
|---|---|
The co-agonist site of NMDA-glutamate receptors: a novel therapeutic target for age-related cognitive decline.
Topics: Adult; Age Factors; Aged; Aging; Animals; Binding Sites; Cognition Disorders; Hippocampus; Humans; M | 2014 |
Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Cognition Disorders; Glycine; Humans; | 2014 |
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Dopamine; Glycine; Humans; Receptors, N-Methyl-D | 2015 |
When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia.
Topics: Acoustic Stimulation; Adult; Attention; Auditory Cortex; Auditory Perceptual Disorders; Brain-Derive | 2009 |
Treatment of negative and cognitive symptoms.
Topics: Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Glycine; Humans; Receptors, | 1999 |
3 trials available for serine and Cognition Disorders
| Article | Year |
|---|---|
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Contingent Negat | 2018 |
The effect of D-serine administration on cognition and mood in older adults.
Topics: Adult; Aged; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies | 2016 |
High dose D-serine in the treatment of schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Cognition Di | 2010 |
38 other studies available for serine and Cognition Disorders
| Article | Year |
|---|---|
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
Topics: Amino Acids; Animals; Autism Spectrum Disorder; Cognition; Cognition Disorders; Cycloserine; Dose-Re | 2020 |
Astrocytic signaling supports hippocampal-prefrontal theta synchronization and cognitive function.
Topics: Animals; Astrocytes; Cognition; Cognition Disorders; Doxycycline; Glial Fibrillary Acidic Protein; G | 2017 |
Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury.
Topics: Animals; Brain Injuries, Traumatic; Cognition; Cognition Disorders; Isoxazoles; Male; Mice; Mice, In | 2018 |
Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
Topics: Alzheimer Disease; Animals; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, | 2018 |
Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognition Disorders; Dendritic Spines; Disease Models, A | 2013 |
Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life.
Topics: Adult; Age of Onset; Aged; Alzheimer Disease; Amyloid beta-Peptides; Brain; Brain Waves; Cognition D | 2014 |
Impaired D-serine-mediated cotransmission mediates cognitive dysfunction in epilepsy.
Topics: Allosteric Regulation; Animals; Binding Sites; Cognition Disorders; D-Amino-Acid Oxidase; Disease Mo | 2013 |
Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice.
Topics: Age Factors; Animals; Axonal Transport; Cognition Disorders; Disease Progression; Exploratory Behavi | 2014 |
A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.
Topics: Adult; Brain; Cognition Disorders; Diffusion Tensor Imaging; Female; Glycine; Humans; Leucine-Rich R | 2014 |
The role of hippocampal tau protein phosphorylation in isoflurane-induced cognitive dysfunction in transgenic APP695 mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Cognition; Cognition D | 2014 |
D-serine prevents cognitive deficits induced by acute stress.
Topics: Acute Disease; Animals; Cognition Disorders; Corticosterone; Disease Models, Animal; Glycine; Hippoc | 2014 |
Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Chromatography, Liquid; Cognition Disorders; D-Amin | 2015 |
Two new cases of serine deficiency disorders treated with l-serine.
Topics: Adult; Amino Acid Metabolism, Inborn Errors; Amino Acids; Carbohydrate Metabolism, Inborn Errors; Ch | 2016 |
Amyloid precursor protein maintains constitutive and adaptive plasticity of dendritic spines in adult brain by regulating D-serine homeostasis.
Topics: Amyloid beta-Protein Precursor; Animals; Brain; Cognition Disorders; Dendritic Spines; Female; Homeo | 2016 |
The extensive nitration of neurofilament light chain in the hippocampus is associated with the cognitive impairment induced by amyloid beta in mice.
Topics: Amyloid beta-Peptides; Animals; Cognition Disorders; Cytoskeleton; Hippocampus; Male; Mice; Mice, In | 2008 |
The Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain morphology in schizophrenia.
Topics: Adult; Brain; Cognition Disorders; Cysteine; Female; Frontal Lobe; Gene Frequency; Genetic Predispos | 2009 |
Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits.
Topics: Animals; Aromatase; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cognition Disorders; Disease | 2010 |
Dysregulation of mTOR signaling in fragile X syndrome.
Topics: Adaptor Proteins, Signal Transducing; Animals; CA1 Region, Hippocampal; Carrier Proteins; Cell Cycle | 2010 |
A novel mutation in the predicted TMIII domain of the PSEN2 gene in an Italian pedigree with atypical Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Cysteine; DNA Mutational Analysis; Female; Humans; Ita | 2010 |
Neuropsychological function in patients with a single gene mutation associated with autosomal dominant nocturnal frontal lobe epilepsy.
Topics: Adult; Association Learning; Circadian Rhythm; Cognition Disorders; Epilepsy, Frontal Lobe; Female; | 2010 |
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Cerebral Cortex; Cognition Disorders; Electrophoresis, Gel | 2010 |
Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Blood Platelets; Cognition Disorde | 2011 |
Acute stress induces contrasting changes in AMPA receptor subunit phosphorylation within the prefrontal cortex, amygdala and hippocampus.
Topics: Amygdala; Animals; Brain Mapping; Cognition Disorders; Corticosterone; Frontal Lobe; Glutamic Acid; | 2010 |
Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; | 2011 |
Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Female; Genetic Predisposition to Disease; Glycine; Hu | 2011 |
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.
Topics: Age Factors; Alzheimer Disease; Animals; Antibodies; Cognition Disorders; Disease Models, Animal; En | 2012 |
Phosphorylation of HSP27 by protein kinase D is essential for mediating neuroprotection against ischemic neuronal injury.
Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Cortex; Cognition Disorders; Disease Models, Anim | 2012 |
D-Serine ameliorates neonatal PolyI:C treatment-induced emotional and cognitive impairments in adult mice.
Topics: Affective Symptoms; Animals; Animals, Newborn; Anti-Anxiety Agents; Behavior, Animal; Central Nervou | 2012 |
No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Alanine; Antipsychotic Agents; Basal Ganglia Diseases; Biomarkers; Brief Ps | 2012 |
Prenatal administration of morphine decreases CREBSerine-133 phosphorylation and synaptic plasticity range mediated by glutamatergic transmission in the hippocampal CA1 area of cognitive-deficient rat offspring.
Topics: Animals; Cognition Disorders; Cyclic AMP Response Element-Binding Protein; Down-Regulation; Excitato | 2003 |
Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Blotting, Western; Case-Contro | 2006 |
Novel mutation in the ceruloplasmin gene causing a cognitive and movement disorder with diabetes mellitus.
Topics: Ceruloplasmin; Cognition Disorders; Diabetes Complications; DNA Mutational Analysis; Exons; Female; | 2006 |
The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients.
Topics: Alleles; Alzheimer Disease; Apolipoprotein E4; Cognition Disorders; Disease Progression; Follow-Up S | 2007 |
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine.
Topics: Animals; Brain; Brain Chemistry; Cognition Disorders; Disease Models, Animal; Drug Administration Sc | 2008 |
D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Clozapine; Cognition; Cognition Disorders; Dizo | 2008 |
The impaired long-term potentiation in the CA1 field of the hippocampus of cognitive deficient microencephalic rats is restored by D-serine.
Topics: 2-Amino-5-phosphonovalerate; Animals; Brain; Cognition Disorders; Electric Stimulation; Electrophysi | 1993 |
Concentrations of glycine and serine in cerebrospinal fluid during disturbed consciousness; a study of the therapeutic effect of thyrotropin-releasing hormone on the consciousness level.
Topics: Adolescent; Adult; Aged; Amino Acids; Cognition Disorders; Consciousness Disorders; Female; Glycine; | 1986 |
[Metrizamide encephalopathy in a child with hydrocephalus--effects of L-threo-DOPS on persistent disturbance of consciousness and L-dopa on extrapyramidal symptoms].
Topics: Basal Ganglia Diseases; Brain; Brain Diseases; Child; Cognition Disorders; Consciousness Disorders; | 1988 |